Qiagen ( (QGEN) ) just unveiled an update.
QIAGEN N.V. announced a manager’s transaction involving Roland Sackers, a member of the managing body, who executed a release of 8,980 Performance Stock Units granted in 2015. This transaction resulted in the receipt of 4,736 common shares after net share settlement, with some shares withheld to cover related expenses. The transaction, linked to share option programs, reflects the company’s ongoing financial strategies and impacts its stock management practices.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on enabling customers to gain valuable insights from the building blocks of life, with a market presence in various global stock exchanges including Frankfurt, NYSE, and SIX.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.